Risk of Chemotherapy-Induced Peripheral Neuropathy in Large Population-Based Cohorts of Elderly Patients With Breast, Ovarian, and Lung Cancer
Authors:
- 1 March 2010
- journal article
- research article
- Published by Wolters Kluwer Health in American Journal of Therapeutics
- Vol. 17 (2) , 148-158
Abstract
There is little information on chemotherapy-induced peripheral neuropathy (PN) for community-dwelling patients with cancer. We studied 65,316 patients with breast cancer, 9242 with ovarian cancer, and 86,278 with non-small cell lung cancer from 1991 through 2002 identified from the 16 areas of Surveillance, Epidemiology and End Results. The incidence density of PN was 15.3, 21.5, and 18.3 per 1000 person-years for patients with breast, ovarian, and lung cancer who received platinum-taxane combination chemotherapy, respectively. Patients with breast, ovarian, and lung cancer receiving taxanes were more than twice as likely to develop PN compared with those not receiving chemotherapy (adjusted hazard ratio = 2.22, 95% confidence interval = 1.85-2.66 in patients with breast cancer), whereas patients who received platinum-taxane combination chemotherapy were more than 3 times as likely to develop PN compared with women who did not receive chemotherapy (adjusted hazard ratio = 3.33, 95% confidence interval = 2.05-5.05). In patients with ovarian or lung cancer receiving taxanes or platinum-taxane combination therapy, the risk of PN was increased with increasing number of chemotherapy cycles. These findings remained similar after adjusting for the history of preexisting PN or diabetes. Close monitoring for PN in patients receiving taxanes alone or in combination with platinum compounds may be warranted.Keywords
This publication has 32 references indexed in Scilit:
- Chemotherapy‐induced neuropathyJournal of the Peripheral Nervous System, 2008
- Neurologic complications of chemotherapy agentsCurrent Opinion in Neurology, 2007
- Peripheral neuropathy: A persisting challenge in paclitaxel-based regimesEuropean Journal of Cancer, 2006
- Paclitaxel After Doxorubicin Plus Cyclophosphamide As Adjuvant Chemotherapy for Node-Positive Breast Cancer: Results From NSABP B-28Journal of Clinical Oncology, 2005
- Failure of Higher-Dose Paclitaxel to Improve Outcome in Patients With Metastatic Breast Cancer: Cancer and Leukemia Group B Trial 9342Journal of Clinical Oncology, 2004
- Comparative neurotoxicity of weekly non-break paclitaxel infusions over 1 versus 3 hAnti-Cancer Drugs, 2003
- Phase I and Pharmacokinetic Study of Two Different Schedules of Oxaliplatin, Irinotecan, Fluorouracil, and Leucovorin in Patients With Solid TumorsJournal of Clinical Oncology, 2003
- A comparison of the incidence, duration, and degree of the neurologic toxicities of cisplatin-paclitaxel (PT) and cisplatin-cyclophosphamide (PC)International Journal of Gynecological Cancer, 2003
- Weekly, high‐dose paclitaxel in advanced lung carcinomaCancer, 2003
- The Impact of Diabetes Mellitus on the Toxicity of Therapy for Advanced Ovarian CancerGynecologic Oncology, 1996